AAPL319.29-8.92 (-2.72%) ▼|ABBV257.28-2.93 (-1.13%) ▼|ABT109.88+1.09 (+1.00%) ▲|ACN188.07-5.05 (-2.62%) ▼|ADBE267.50-18.25 (-6.39%) ▼|AMAT454.82+18.91 (+4.34%) ▲|AMD469.36+13.20 (+2.89%) ▲|AMGN437.81-6.31 (-1.42%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN255.93-2.97 (-1.15%) ▼|AVGO355.98-1.19 (-0.33%) ▼|AXP326.30-3.52 (-1.07%) ▼|BA210.42-0.09 (-0.04%) ▼|BAC62.02-0.70 (-1.12%) ▼|BKNG193.95-1.19 (-0.61%) ▼|BLK1,119.55-6.60 (-0.59%) ▼|BMY66.94-1.15 (-1.69%) ▼|BNY164.42+0.09 (+0.05%) ▲|BRK-B506.39-1.74 (-0.34%) ▼|C135.61-2.53 (-1.83%) ▼|CAT813.09+12.95 (+1.62%) ▲|CL89.84-0.26 (-0.28%) ▼|CMCSA26.46-0.20 (-0.73%) ▼|COF219.53-0.97 (-0.44%) ▼|COP134.42-1.30 (-0.96%) ▼|COST916.97-8.44 (-0.91%) ▼|CRM259.49-4.94 (-1.87%) ▼|CSCO109.14+0.53 (+0.49%) ▲|CVS96.97-0.24 (-0.24%) ▼|CVX208.62-2.70 (-1.28%) ▼|DE696.80+2.39 (+0.34%) ▲|DHR207.00-4.04 (-1.91%) ▼|DIS105.45-1.71 (-1.60%) ▼|DUK121.12-0.28 (-0.23%) ▼|EMR152.34+2.13 (+1.42%) ▲|FDX322.70-1.61 (-0.50%) ▼|GD359.51-6.36 (-1.74%) ▼|GE333.36-0.13 (-0.04%) ▼|GEV944.08+2.24 (+0.24%) ▲|GILD150.45-0.78 (-0.51%) ▼|GM87.33+0.29 (+0.33%) ▲|GOOG334.30-4.78 (-1.41%) ▼|GOOGL337.61-4.65 (-1.36%) ▼|GS1,025.29-12.64 (-1.22%) ▼|HD319.34+1.27 (+0.40%) ▲|HON208.23+0.60 (+0.29%) ▲|IBM234.15-0.57 (-0.24%) ▼|INTC95.01+3.34 (+3.64%) ▲|INTU333.77-10.53 (-3.06%) ▼|ISRG365.59-4.24 (-1.15%) ▼|JNJ276.25-2.18 (-0.78%) ▼|JPM355.45-6.62 (-1.83%) ▼|KO88.75-0.07 (-0.07%) ▼|LIN481.08-1.11 (-0.23%) ▼|LLY1,142.88-16.72 (-1.44%) ▼|LMT526.66-6.29 (-1.18%) ▼|LOW201.98+0.08 (+0.04%) ▲|LRCX302.14+9.48 (+3.24%) ▲|MA580.05-5.66 (-0.97%) ▼|MCD256.73-2.90 (-1.12%) ▼|MDLZ61.71+0.26 (+0.42%) ▲|MDT94.29+1.19 (+1.28%) ▲|META612.70+2.02 (+0.33%) ▲|MMM168.73+0.42 (+0.25%) ▲|MO69.28-0.22 (-0.31%) ▼|MRK150.76-1.58 (-1.04%) ▼|MS214.63-2.52 (-1.16%) ▼|MSFT500.52-9.60 (-1.88%) ▼|MU999.00+40.84 (+4.26%) ▲|NEE83.76-0.30 (-0.36%) ▼|NFLX79.58-3.09 (-3.74%) ▼|NKE38.31-0.47 (-1.20%) ▼|NOW140.66-4.94 (-3.39%) ▼|NVDA232.00+3.55 (+1.55%) ▲|ORCL157.58+3.54 (+2.30%) ▲|PEP138.67+0.13 (+0.09%) ▲|PFE28.56-0.25 (-0.87%) ▼|PG146.68-0.24 (-0.16%) ▼|PLTR175.86-6.67 (-3.65%) ▼|PM184.44-1.73 (-0.93%) ▼|QCOM168.90+0.33 (+0.20%) ▲|RTX200.62-1.51 (-0.74%) ▼|SBUX105.89+0.07 (+0.07%) ▲|SCHW109.82-0.56 (-0.51%) ▼|SO88.78-0.03 (-0.03%) ▼|SPG211.95+0.44 (+0.21%) ▲|T26.18-0.01 (-0.02%) ▼|TMO612.13-6.30 (-1.02%) ▼|TMUS181.93-6.09 (-3.24%) ▼|TSLA352.69-23.68 (-6.29%) ▼|TXN257.46+3.63 (+1.43%) ▲|UBER76.63+0.67 (+0.88%) ▲|UNH398.39-2.56 (-0.64%) ▼|UNP289.85+0.71 (+0.25%) ▲|UPS103.00-0.51 (-0.49%) ▼|USB63.57+0.04 (+0.06%) ▲|V375.47-3.24 (-0.86%) ▼|VZ50.66+0.08 (+0.15%) ▲|WFC89.54+0.35 (+0.39%) ▲|WMT108.64+0.22 (+0.20%) ▲|XOM160.24-2.00 (-1.23%) ▼|AAPL319.29-8.92 (-2.72%) ▼|ABBV257.28-2.93 (-1.13%) ▼|ABT109.88+1.09 (+1.00%) ▲|ACN188.07-5.05 (-2.62%) ▼|ADBE267.50-18.25 (-6.39%) ▼|AMAT454.82+18.91 (+4.34%) ▲|AMD469.36+13.20 (+2.89%) ▲|AMGN437.81-6.31 (-1.42%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN255.93-2.97 (-1.15%) ▼|AVGO355.98-1.19 (-0.33%) ▼|AXP326.30-3.52 (-1.07%) ▼|BA210.42-0.09 (-0.04%) ▼|BAC62.02-0.70 (-1.12%) ▼|BKNG193.95-1.19 (-0.61%) ▼|BLK1,119.55-6.60 (-0.59%) ▼|BMY66.94-1.15 (-1.69%) ▼|BNY164.42+0.09 (+0.05%) ▲|BRK-B506.39-1.74 (-0.34%) ▼|C135.61-2.53 (-1.83%) ▼|CAT813.09+12.95 (+1.62%) ▲|CL89.84-0.26 (-0.28%) ▼|CMCSA26.46-0.20 (-0.73%) ▼|COF219.53-0.97 (-0.44%) ▼|COP134.42-1.30 (-0.96%) ▼|COST916.97-8.44 (-0.91%) ▼|CRM259.49-4.94 (-1.87%) ▼|CSCO109.14+0.53 (+0.49%) ▲|CVS96.97-0.24 (-0.24%) ▼|CVX208.62-2.70 (-1.28%) ▼|DE696.80+2.39 (+0.34%) ▲|DHR207.00-4.04 (-1.91%) ▼|DIS105.45-1.71 (-1.60%) ▼|DUK121.12-0.28 (-0.23%) ▼|EMR152.34+2.13 (+1.42%) ▲|FDX322.70-1.61 (-0.50%) ▼|GD359.51-6.36 (-1.74%) ▼|GE333.36-0.13 (-0.04%) ▼|GEV944.08+2.24 (+0.24%) ▲|GILD150.45-0.78 (-0.51%) ▼|GM87.33+0.29 (+0.33%) ▲|GOOG334.30-4.78 (-1.41%) ▼|GOOGL337.61-4.65 (-1.36%) ▼|GS1,025.29-12.64 (-1.22%) ▼|HD319.34+1.27 (+0.40%) ▲|HON208.23+0.60 (+0.29%) ▲|IBM234.15-0.57 (-0.24%) ▼|INTC95.01+3.34 (+3.64%) ▲|INTU333.77-10.53 (-3.06%) ▼|ISRG365.59-4.24 (-1.15%) ▼|JNJ276.25-2.18 (-0.78%) ▼|JPM355.45-6.62 (-1.83%) ▼|KO88.75-0.07 (-0.07%) ▼|LIN481.08-1.11 (-0.23%) ▼|LLY1,142.88-16.72 (-1.44%) ▼|LMT526.66-6.29 (-1.18%) ▼|LOW201.98+0.08 (+0.04%) ▲|LRCX302.14+9.48 (+3.24%) ▲|MA580.05-5.66 (-0.97%) ▼|MCD256.73-2.90 (-1.12%) ▼|MDLZ61.71+0.26 (+0.42%) ▲|MDT94.29+1.19 (+1.28%) ▲|META612.70+2.02 (+0.33%) ▲|MMM168.73+0.42 (+0.25%) ▲|MO69.28-0.22 (-0.31%) ▼|MRK150.76-1.58 (-1.04%) ▼|MS214.63-2.52 (-1.16%) ▼|MSFT500.52-9.60 (-1.88%) ▼|MU999.00+40.84 (+4.26%) ▲|NEE83.76-0.30 (-0.36%) ▼|NFLX79.58-3.09 (-3.74%) ▼|NKE38.31-0.47 (-1.20%) ▼|NOW140.66-4.94 (-3.39%) ▼|NVDA232.00+3.55 (+1.55%) ▲|ORCL157.58+3.54 (+2.30%) ▲|PEP138.67+0.13 (+0.09%) ▲|PFE28.56-0.25 (-0.87%) ▼|PG146.68-0.24 (-0.16%) ▼|PLTR175.86-6.67 (-3.65%) ▼|PM184.44-1.73 (-0.93%) ▼|QCOM168.90+0.33 (+0.20%) ▲|RTX200.62-1.51 (-0.74%) ▼|SBUX105.89+0.07 (+0.07%) ▲|SCHW109.82-0.56 (-0.51%) ▼|SO88.78-0.03 (-0.03%) ▼|SPG211.95+0.44 (+0.21%) ▲|T26.18-0.01 (-0.02%) ▼|TMO612.13-6.30 (-1.02%) ▼|TMUS181.93-6.09 (-3.24%) ▼|TSLA352.69-23.68 (-6.29%) ▼|TXN257.46+3.63 (+1.43%) ▲|UBER76.63+0.67 (+0.88%) ▲|UNH398.39-2.56 (-0.64%) ▼|UNP289.85+0.71 (+0.25%) ▲|UPS103.00-0.51 (-0.49%) ▼|USB63.57+0.04 (+0.06%) ▲|V375.47-3.24 (-0.86%) ▼|VZ50.66+0.08 (+0.15%) ▲|WFC89.54+0.35 (+0.39%) ▲|WMT108.64+0.22 (+0.20%) ▲|XOM160.24-2.00 (-1.23%) ▼|
28.3 C
New York
Friday, September 4, 2026

Tag: cell

newssourceFORcompanyinformationcontent1releasesmarket

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company’s HOPE-3 Phase 3 trial.

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

Complex Small Molecules Are Changing Drug R&D

WuXi AppTec details how structural complexity in protein degraders, covalent agents, and kinase programs is reshaping what integrated CRDMOs must deliver.

Beyond Injections: S-CELL Unveils Breakthrough “Endogenous GLP-1” Formula Powered by Akkermansia P9 Signaling and CoreBiome® Technology

HONG KONG, June 26, 2026 /PRNewswire/ -- S-CELL, a premier innovator in cellular health and anti-aging biotechnology, today announced the launch of its advanced...

CRRC Launches XUANKUN (VELFORCE) for Central Asia Industrial Rail at China-Eurasia Expo

URUMQI, China, June 26, 2026 /PRNewswire/ -- At the 9th China-Eurasia Expo, CRRC Corporation Limited (CRRC) unveiled XUANKUN (VELFORCE), a serialized new-energy locomotive brand engineered...

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Sunwoda Launches Next-Generation 588Ah-Based ESS Platform at ees Europe 2026 and Announces Safety and EU Compliance Milestones

MUNICH, June 26, 2026 /PRNewswire/ -- Sunwoda, a full-scenario energy storage solution provider, participated in ees Europe 2026 in Munich, Germany, showcasing a broad...

Herbalife and IIT Madras Launch India’s First Centre of Excellence on Plant Cell Fermentation Technology

Herbalife–IIT Madras Centre of Excellence aims to position India as a global leader in sustainable biomanufacturing and next-generation plant-derived health and wellness productsCHENNAI, India,...

Circulate Health announces exclusive partnership with Reborne to bring its advanced therapeutic plasma exchange protocols to UK for first time

LONDON, June 25, 2026 /PRNewswire/ -- Circulate Health and Reborne have today announced an exclusive partnership that will see Reborne become the first UK hospital...

Circulate Health announces exclusive partnership with Reborne to bring its advanced therapeutic plasma exchange protocols to UK for first time

LONDON, June 25, 2026 /PRNewswire/ -- Circulate Health and Reborne have today announced an exclusive partnership that will see Reborne become the first UK hospital...

Cold Chain Packaging Market Size to Reach USD 93.1 Billion by 2033, Driven by Biopharmaceutical Expansion, E-commerce Growth, and Rising Demand for Temperature-Sensitive Logistics

Global market projected to grow at a CAGR of 13.5% from 2026 to 2033 as pharmaceutical, food, and healthcare industries increasingly rely on advanced...

Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility

Optimized capital structure, retiring short-term maturing debt

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —

[Latest] Global Stem Cell Culture Media Market Size/Share Worth USD 2714 Million by 2035 at a 13.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report,...

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Stem Cell Culture Media Market size & share revenue was valued at approximately USD 765 Million in 2025 and is expected to reach USD 868 Million in 2026 and is expected to reach around USD 2714 Million by 2035, at a CAGR of 13.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are PAN Biotech GmbH, Sartorius AG, Cytiva, Lonza Group AG, Corning Incorporated, STEMCELL Technologies Inc., FUJIFILM Irvine Scientific Inc., Takara Bio Inc., Miltenyi Biotec B.V. & Co. KG, PromoCell GmbH, Biological Industries Ltd., CellGenix GmbH, Thermo Fisher Scientific Inc., HiMedia Laboratories Pvt. Ltd., Merck KGaA and others. 
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Stem Cell Culture Media Market size & share revenue was valued at approximately USD 765 Million in 2025 and is expected to reach USD 868 Million in 2026 and is expected to reach around USD 2714 Million by 2035, at a CAGR of 13.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are PAN Biotech GmbH, Sartorius AG, Cytiva, Lonza Group AG, Corning Incorporated, STEMCELL Technologies Inc., FUJIFILM Irvine Scientific Inc., Takara Bio Inc., Miltenyi Biotec B.V. & Co. KG, PromoCell GmbH, Biological Industries Ltd., CellGenix GmbH, Thermo Fisher Scientific Inc., HiMedia Laboratories Pvt. Ltd., Merck KGaA and others.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCell

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers